Correspondence on 'Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial'

被引：1
|
作者：
Wang, Weijie [1 ]
Lee, Yung-Heng [2 ,3 ,4 ]
Wei, James Cheng Chung [5 ,6 ,7 ]
机构：
[1] Zhejiang Chinese Med Univ, Dept Rheumatol, Affiliated Hosp 2, Hangzhou, Peoples R China
[2] Minghsin Univ Sci & Technol, Dept Sr Serv Ind management, Hsinchu, Taiwan
[3] Shu Te Univ, Dept Recat & Sport Management, Kaohsiung, Taiwan
[4] Cishan Hosp, Dept Orthoped, Minist Hlth & Welf, Kaohsiung, Taiwan
[5] Chung Shan Med Univ, Inst Med, Taichung 404, Taiwan
[6] Chung Shan Med Univ Hosp, Dept Allergy Immunol & Rheumatol Taiwan, Taichung, Taiwan
[7] China Med Univ, Grad Inst Integrated Med, Taichung, Taiwan
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2021年
基金：
中国国家自然科学基金;
关键词：
spondylitis; ankylosing; epidemiology; arthritis;
D O I：
10.1136/annrheumdis-2021-220938
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：1
相关论文
共 45 条
  • [41] Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)
    Paton, Nicholas I.
    Stoehr, Wolfgang
    Arenas-Pinto, Alejandro
    Clarke, Amanda
    Williams, Ian
    Johnson, Margaret
    Orkin, Chloe
    Chen, Fabian
    Lee, Vincent
    Winston, Alan
    Gompels, Mark
    Fox, Julie
    Sanders, Karen
    Dunn, David T.
    ECLINICALMEDICINE, 2024, 69
  • [42] Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
    Garber, Alan J.
    King, Allen B.
    Del Prato, Stefano
    Sreenan, Seamus
    Balci, Mustafa K.
    Munoz-Torres, Manuel
    Rosenstock, Julio
    Endahl, Lars A.
    Francisco, Ann Marie Ocampo
    Hollander, Priscilla
    LANCET, 2012, 379 (9825): : 1498 - 1507
  • [43] Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
    Heller, Simon
    Buse, John
    Fisher, Miles
    Garg, Satish
    Marre, Michel
    Merker, Ludwig
    Renard, Eric
    Russell-Jones, David
    Philotheou, Areti
    Francisco, Ann Marie Ocampo
    Pei, Huiling
    Bode, Bruce
    LANCET, 2012, 379 (9825): : 1489 - 1497
  • [44] Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin- treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, trial
    Mathieu, Chantal
    Asbjornsdottir, Bjorg
    Bajaj, Harpreet S.
    Lane, Wendy
    Matos, Ana Laura S. A.
    Murthy, Sreenivasa
    Stachlewska, Karolina
    Rosenstock, Julio
    LANCET, 2023, 401 (10392): : 1929 - 1940
  • [45] The Efficacy and Safety of Insulin Degludec Given in Variable Once-Daily Dosing Intervals Compared With Insulin Glargine and Insulin Degludec Dosed at the Same Time Daily A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
    Meneghini, Luigi
    Atkin, Stephen L.
    Gough, Stephen C. L.
    Raz, Itamar
    Blonde, Lawrence
    Shestakova, Marina
    Bain, Stephen
    Johansen, Thue
    Begtrup, Kamilla
    Birkeland, Kare I.
    DIABETES CARE, 2013, 36 (04) : 858 - 864
12345